Filing Flows › bioAffinity Technologies (BIAF) › Q2 2026
bioAffinity Technologies (BIAF) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
bioAffinity Technologies (BIAF) reported revenue of $1.5M for the second quarter 2026 (Q2 2026), +19% from a year earlier and +12% from the quarter before. Operating margin was -220.8%, net loss $3.4M (222.8% of revenue).
bioAffinity Technologies, Q2 2026: revenue $1.5M (+19% year over year), operating margin -220.8%, net loss $3.4M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | +12% | +19% |
| Operating profit | −$3.3M | — | — |
| Net earnings | −$3.4M | — | — |
| Operating cash flow | −$3.2M | — | — |
What changed
Revenue was $1.5M in Q2 2026, up 19% year over year and up 12% from the previous quarter. Health Care, Patient Service was the largest line at 82% of revenue. Health Care, Patient Service added $302K year over year (up 32%), 125% of the total change. Other Revenues declined 58%.
Operating costs exceeded revenue by $3.3M, an operating margin of -220.8%. Total costs grew 28% against revenue growth of 19%. The fastest-growing cost line was SG&A (+29%). The quarter ended with a net loss of $3.4M, narrower than the previous quarter's $3.6M loss.
Operating cash flow was −$3.2M. Non-cash charges added back $62K of depreciation and amortization and $785K of share-based compensation. Working capital and other items used $682K. Capital expenditures of $90K exceeded it, leaving free cash flow of −$3.3M.
Questions
What was bioAffinity Technologies' revenue in the second quarter 2026?
bioAffinity Technologies (BIAF) reported revenue of $1.5M for the second quarter 2026 (Q2 2026), +19% from a year earlier and +12% from the quarter before.
Was bioAffinity Technologies profitable in the second quarter 2026?
Operating loss was $3.3M (-220.8% of revenue) and net loss $3.4M.